Inhibition of CTLA or PD-1 monoclonal antibodies is the most promising treatment approach for many cancers, including the microsatellite instability (MSI) -high advanced CRC (Messersmith, 2019). This evidence concerns the gene PDCD1 and colorectal carcinoma.